A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).

Tie Zhou,Dingwei Ye,Zhongquan Sun,Qinggui Meng,Dalin He,Guowei Shi,Jie Jin,Weibing Sun,Lijun Chen,Ben Liu,Jingen Wang,Jiwen Cheng,Zhiquan Hu, Yong Yang,Xishuang Song,Yinhuai Wang,Cheng Fu,Qiaoxia Zhou,Youzhi Tong,Ying-Hao Sun

JOURNAL OF CLINICAL ONCOLOGY（2021）

Cited 1|Views30

No score

Abstract

108Background: GT0918 is a 2nd generation of AR antagonist and capability to down-regulate AR level. This study is an open-label, randomized, multicenter, Ph II study to evaluate the safety and eff...

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined